All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
GvHD prophylaxis with donor lymphocyte infusion in patients treated with PTCy
Bookmark this article
|
A multicenter retrospective cohort study assessed the safety and efficacy of DLI in 162 patients treated with PTCy and transplanted between 2015 and 2022 within the Center for Immuno-Oncology at the National Cancer Institute.1 A total of 21 patients received ≥1 DLI after 22 PTCy-based transplants. Results were published in Bone Marrow Transplantationby Shanmugasundaram et al.1 |
| Key learnings |
| Low incidences of aGvHD (7.8%), CRS (7.8%), and cGvHD (2.6%) were observed in patients who received DLI, all of whom underwent serotherapy-containing pre-HCT conditioning. |
| The CR rate with DLI was low overall (18.4%), and in patients with disease relapse (11%) and mixed chimerism or delayed engraftment (15%). |
| The CR rate was higher in patients who received serotherapy conditioning pre-transplant vs those who did not (30% vs 4.3%). |
| Although DLI was safe and lowered the risk of GvHD in patients treated with PTCy, it demonstrated limited efficacy in preventing disease relapse or achieving long-term disease control. Further research to identify strategies to enhance the efficacy of DLI is needed. |
Abbreviations: aGvHD, acute GvHD; cGvHD, chronic GvHD; CR, complete response; CRS, cytokine release syndrome; DLI, donor lymphocyte infusion; GvHD, graft-versus-host disease; PTCy, post-transplant cyclophosphamide.
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox